Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr Vladislav Sandler and non-executive director Peter Redmond talked with Proactive's Stephen Gunnion about key developments, including an Extraordinary General Meeting (EGM) to approve a share consolidation. Redmond explained the reasoning behind the consolidation, aimed at attracting institutional investors and enhancing the company’s capital structure as it moves closer to clinical trials for its HEMO-CAR-T lead therapy.
Sandler provided updates on regulatory progress, highlighting approvals from both a scientific review committee and an internal review board (IRB) at an unnamed cancer centre, paving the way for clinical trials. He emphasised, “We are actually there... the hospital will start patient recruitment once we receive the final letter.”
The interview also touched on strategic moves to position the company favourably with larger pharmaceutical companies and investors. Redmond described this as “a vital point” for accessing quality funds and advancing Hemogenyx’s product pipeline.
